We utilize an extensive network of international suppliers for procuring raw materials, intermediates, packaging materials, technical components and services to deliver our innovative medications worldwide.
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.